Pyxis Oncology, Inc.PYXS
...Loading PYXS Peers...
Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors; and PYX-102, an investigational immune-therapeutic for treatment of solid tumors. The company's antibody drug conjugate (ADC) product candidates comprise of PYX-201, an investigational novel ADC to treat NSCLC, breast cancer, and other solid tumors; PYX-202, an investigational novel ADC for treatment of SCLC, soft tissue sarcoma, and other solid tumors; and PYX-203, an investigational ADC for the treatment of acute myeloid leukemia and myeloid dysplastic syndrome. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
54 Employees
CEO : Dr. Lara S. Sullivan M.D., MBA
Address : 35 Cambridgepark Drive, Cambridge,MA, US, - 02140,
| Key Excutives | Designation |
|---|---|
| Dr. Jan Pinkas Ph.D. | Chief Scientific Officer |
| Dr. Lara S. Sullivan M.D., MBA | Chief Executive Officer, President & Director |
| Ms. Pamela Yanchik Connealy M.B.A. | Chief Financial Officer & Chief Operating Officer |
| Dr. Balu N. Balasubramanian Ph.D. | Interim Chief Technology Officer |
| Dr. Charles T. Gombar Ph.D. | Senior Vice President of Portfolio & Program Management |
| Mr. Stephen T. Worsley MBA | Senior Vice President & Chief Business Officer |
| Mr. Jitendra Wadhane | Chief Accounting Officer, Senior Vice President of Finance & Corporate Controller |
| Dr. Ken Kobayashi FACP, M.D. | Chief Medical Officer |